Biolinq key facts
as of Oct 2026- Developer of a biomonitoring health platform designed to improve metabolic health.
- Biolinq is valued at approximately $407.0M as of Oct 2026, set at its later-stage round, Apr 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $312.8M across 8 recorded rounds; the latest was Later Stage VC ($90.0M) in Mar 2025.
- Notable investors include MedTech Innovator, National Institutes of Health, CONNECT(San Diego), Pegasus Tech Ventures, Mark Cuban — 36 tracked in total.
- Biolinq has filed 12 Form Ds with the SEC since 2016, most recently Mar 2025 ($90.0M sold to 45 investors).
- Status: Privately Held (backing).
Valued at $407.0M at its later-stage round, Apr 2025. Nothing has traded since.
- ·The complete investor list: 36 names
- ·Watch Biolinq: the Monday email on marks, rounds and moves
Biolinq funding rounds
8 roundsWho backs Biolinq
36+Biolinq valuation
Biolinq was valued at $407 million at its later-stage round in Apr 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Biolinq raised?
Biolinq has raised $313 million across 8 recorded rounds since 2016. The largest was a $90 million later-stage round in Mar 2025.
Biolinq has filed 12 Form Ds with the SEC since 2016, most recently in Mar 2025 ($90 million sold to 45 investors).
Biolinq investors
36 investors are on record for Biolinq, including MedTech Innovator, National Institutes of Health, CONNECT(San Diego) and Pegasus Tech Ventures. The later-stage round in Mar 2025 drew 45 investors.
About Biolinq
Developer of a biomonitoring health platform designed to improve metabolic health. The company's platform offers a skin-applied, minimally invasive electrochemical biosensor with a potential for multiple analytes, such as glucose, ketones, and lactate, and provides actionable metabolic health insights from multi-analyte wearable sensors, providing patients with personalized health insights and supporting advancements in medicine.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2012
- Employees
- 111
- Website
- biolinq.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.